Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc.…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…